2026-01-13 スタンフォード大学
Participants in the study ate plant-based meals during the fasting period of the trial instead of their usual diet. | Getty Images
<関連情報>
- https://news.stanford.edu/stories/2026/01/crohns-disease-diet-study-research-how-to-relieve-symptoms
- https://www.nature.com/articles/s41591-025-04173-w
軽度から中等度のクローン病患者における断食模倣食:ランダム化比較試験 A fasting-mimicking diet in patients with mild-to-moderate Crohn’s disease: a randomized controlled trial
C. Kulkarni,T. Fardeen,J. Gubatan,J. Ye,K. Jarr,E. Dickson,H. Jang,M. Temby,A. Patel,Y. Jiang,G. Singh,K. Keyashian,S. Streett,E. Ho,G. Barber,S. Singh,D. Limsui,N. Anaizi,L. Becker,S. P. Spencer,D. Mehrish,D. Perelman,V. D. Longo,V. Charu,… S. R. Sinha
Nature Medicine Published:13 January 2026
DOI:https://doi.org/10.1038/s41591-025-04173-w
Abstract
In healthy individuals, short cycles of a fasting-mimicking diet (FMD) decrease systemic inflammatory markers and improve metabolic health. Potential benefits of FMD have not been investigated in Crohn’s disease (CD). We conducted an open-label, randomized, controlled trial to assess the effects of FMD in adults with mild-to-moderate CD. Patients in the FMD group followed an FMD for five consecutive days per month for three consecutive months, returning to their regular baseline diet on non-FMD days. Control participants continued their baseline diet. The primary outcome of clinical response was a reduction in CD Activity Index (CDAI) of at least 70 points or CDAI of ≤150 after the third 5-day diet cycle. Forty-five patients in the FMD group (69.2%) and 14 patients in the control group (43.8%) met the primary outcome of clinical response (P = 0.03). Forty-two patients in the FMD group (64.6%) and 12 patients in the control group (37.5%) achieved the secondary outcome of clinical remission (P = 0.02). There was also a decline from baseline in fecal calprotectin (an inflammatory marker) in the FMD group compared with the control group (-22.0% versus 8.0%, P = 0.03). Exploratory analyses of plasma metabolites and peripheral blood mononuclear cell gene expression revealed post-FMD decreases in key inflammatory lipid mediators and immune-effector transcripts, concordant with reduced CD activity. Together, these findings demonstrate that FMD is superior to a baseline diet for inducing clinical response, clinical remission and biochemical improvement in mild-to-moderate CD, and support further investigation of FMD as an adjunctive therapy for chronic inflammatory diseases. ClinicalTrials.gov registration: NCT04147585.
